Albrecht Piiper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11871624/publications.pdf

Version: 2024-02-01

		279798	3	330143
38	2,136	23		37
papers	citations	h-index		g-index
38	38	38		3684
30	30	30		3004
all docs	docs citations	times ranked		citing authors

#	Article	IF	Citations
1	Hepatocellular Carcinoma Is a Natural Target for Adeno-Associated Virus (AAV) 2 Vectors. Cancers, 2022, 14, 427.	3.7	3
2	Circulating MicroRNAs as Tumor Biomarkers in Hepatocellular Carcinoma. , 2019, , 339-347.		0
3	Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis. PLoS ONE, 2018, 13, e0200855.	2.5	24
4	An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms. ACS Chemical Biology, 2017, 12, 564-573.	3.4	18
5	Cytokeratin 18â€based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients. Liver International, 2016, 36, 1464-1472.	3.9	14
6	Vesicle-associated microRNAs are released from blood cells on incubation of blood samples. Translational Research, 2016, 169, 40-46.	5 . 0	15
7	Serum sphingolipidomic analyses reveal an upregulation of C16- ceramide and sphingosine-1-phosphate in hepatocellular carcinoma. Oncotarget, 2016, 7, 18095-18105.	1.8	63
8	Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis. PLoS ONE, 2015, 10, e0132119.	2. 5	50
9	The role of recent nanotechnology in enhancing the efficacy of radiation therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2015, 1856, 130-143.	7.4	46
10	Single measurement of hemoglobin predicts outcome of HCC patients. Medical Oncology, 2014, 31, 806.	2. 5	23
11	Physico-chemical and toxicological characterization of iron-containing albumin nanoparticles as platforms for medical imaging. Journal of Controlled Release, 2014, 194, 130-137.	9.9	18
12	Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. Journal of Hepatology, 2013, 59, 769-779.	3.7	68
13	Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. European Journal of Cancer, 2013, 49, 3442-3449.	2.8	176
14	Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. Journal of Hepatology, 2013, 58, 956-961.	3.7	95
15	Differential Stability of Cell-Free Circulating microRNAs: Implications for Their Utilization as Biomarkers. PLoS ONE, 2013, 8, e75184.	2.5	167
16	Regulation of Protein Kinase C-related Protein Kinase 2 (PRK2) by an Intermolecular PRK2-PRK2 Interaction Mediated by Its N-terminal Domain. Journal of Biological Chemistry, 2012, 287, 20590-20602.	3.4	22
17	Substrate-Selective Inhibition of Protein Kinase PDK1 by Small Compounds that Bind to the PIF-Pocket Allosteric Docking Site. Chemistry and Biology, 2012, 19, 1152-1163.	6.0	70
18	Reduced Efficacy of the Plk1 Inhibitor BI 2536 on the Progression of Hepatocellular Carcinoma due to Low Intratumoral Drug Levels. Neoplasia, 2012, 14, 410-IN10.	5. 3	45

#	Article	IF	Citations
19	Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity. PLoS ONE, 2012, 7, e30796.	2.5	78
20	Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection. American Journal of Gastroenterology, 2011, 106, 1663-1669.	0.4	171
21	Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e26971.	2,5	120
22	Regulation of the Interaction between Protein Kinase C-related Protein Kinase 2 (PRK2) and Its Upstream Kinase, 3-Phosphoinositide-dependent Protein Kinase 1 (PDK1). Journal of Biological Chemistry, 2009, 284, 30318-30327.	3.4	28
23	Inhibition of the Equilibrative Nucleoside Transporter 1 and Activation of A2A Adenosine Receptors by 8-(4-Chlorophenylthio)-modified cAMP Analogs and Their Hydrolytic Products. Journal of Biological Chemistry, 2009, 284, 32256-32263.	3.4	11
24	RNAse A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1. International Journal of Cancer, 2007, 121, 206-210.	5.1	41
25	Allosteric activation of the protein kinase PDK1 with low molecular weight compounds. EMBO Journal, 2006, 25, 5469-5480.	7.8	104
26	Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. Biochemical Pharmacology, 2006, 71, 702-710.	4.4	130
27	Epac Activation Converts cAMP from a Proliferative into a Differentiation Signal in PC12 Cells. Molecular Biology of the Cell, 2005, 16, 5639-5648.	2.1	102
28	Tumor regression by combination antisense therapy against Plk1 and Bcl-2. Oncogene, 2003, 22, 69-80.	5.9	82
29	Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptor. Biochemical and Biophysical Research Communications, 2003, 301, 848-854.	2.1	22
30	Cholecystokinin Stimulates Extracellular Signal-regulated Kinase through Activation of the Epidermal Growth Factor Receptor, Yes, and Protein Kinase C. Journal of Biological Chemistry, 2003, 278, 7065-7072.	3 . 4	64
31	Cyclic AMP Induces Transactivation of the Receptors for Epidermal Growth Factor and Nerve Growth Factor, Thereby Modulating Activation of MAP Kinase, Akt, and Neurite Outgrowth in PC12 Cells. Journal of Biological Chemistry, 2002, 277, 43623-43630.	3.4	79
32	Subcellular Distribution and Function of Rab3A-D in Pancreatic Acinar AR42J Cells. Biochemical and Biophysical Research Communications, 2001, 287, 746-751.	2.1	23
33	Coupling of endothelin receptors to the ERK/MAP kinase pathway. FEBS Journal, 2001, 268, 5449-5459.	0.2	54
34	Pertussis Toxin Inhibits Cholecystokinin- and Epidermal Growth Factor-Induced Mitogen-Activated Protein Kinase Activation by Disinhibition of the cAMP Signaling Pathway and Inhibition of c-Raf-1. Molecular Pharmacology, 2000, 58, 608-613.	2.3	24
35	Polo-like kinase1, a New Target for Antisense Tumor Therapy. Biochemical and Biophysical Research Communications, 2000, 269, 352-356.	2.1	37
36	Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells. FEBS Letters, 2000, 472, 129-132.	2.8	40

ALBRECHT PIIPER

#	Article	IF	CITATIONS
37	Lipoprotein (a) stimulates mitogen activated protein kinase in human mesangial cells. FEBS Letters, 1998, 441, 205-208.	2.8	6
38	Protein tyrosine phosphorylation in pancreatic acini: differential effects of VIP and CCK. American Journal of Physiology - Renal Physiology, 1997, 273, G1226-G1232.	3.4	3